Is Novo Nordisk (Ozempic) Stock a good buy in 2026, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NYSE: NVO) stock is to Hold NVO stock.
Out of 1 analyst, 0 (0%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 1 (100%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 0 (0%) are recommending NVO as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year NVO price target, the average NVO price target is $41.00, with the highest NVO stock price forecast at $41.00 and the lowest NVO stock price forecast at $41.00.
The Wall Street analyst predicted that Novo Nordisk (Ozempic)'s share price could fall to $41.00 by Mar 2, 2027. The average Novo Nordisk (Ozempic) stock price prediction forecasts a potential downside of 13.54% from the current NVO share price of $47.42.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.